{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T21:22:26Z","timestamp":1773696146266,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.pbb.2023.173523","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T02:32:11Z","timestamp":1675045931000},"page":"173523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Differentially regulated targets in the fast-acting antidepressant effect of (R)-ketamine: A systems biology approach"],"prefix":"10.1016","volume":"223","author":[{"given":"Ellen","family":"Scotton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Lenz","family":"Casa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda Pessi","family":"de Abreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scheila","family":"de Avila e Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata Luiza Boff","family":"Wilges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos Vinicius","family":"Rossetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiza Paul","family":"G\u00e9a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriane R.","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2023.173523_bb0005","unstructured":"Ad\u00e3es, n.d.Ad\u00e3es, S. (n.d.) What is glutamate? An examination of the funcions, pathways and excitation of the glutamate neurotransmitter. Dispon\u00edvel em: <https:\/\/neurohacker.com\/what-is-glutamate>. Acesso em: 17 abr. 2022."},{"key":"10.1016\/j.pbb.2023.173523_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2019.00430","article-title":"Amyloid beta and microRNAs in Alzheimer's disease","volume":"13","author":"Amakiri","year":"2019","journal-title":"Front. Neurosci."},{"issue":"7354","key":"10.1016\/j.pbb.2023.173523_bb0015","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2023.173523_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2022.886619","article-title":"Brain structural and functional changes in cognitive impairment due to Alzheimer's disease","volume":"13","author":"\u00c1vila-Villanueva","year":"2022","journal-title":"Front. Psychol."},{"issue":"51","key":"10.1016\/j.pbb.2023.173523_bb0025","doi-asserted-by":"crossref","first-page":"19535","DOI":"10.1073\/pnas.0608492103","article-title":"Synapse-specific regulation of AMPA receptor function by PSD-95","volume":"103","author":"B\u00e9\u00efque","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.pbb.2023.173523_bb0030","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.pbb.2023.173523_bb0035","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrn1846","article-title":"New approaches to antidepressant drug discovery: beyond monoamines","volume":"7","author":"Berton","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"issue":"sup1","key":"10.1016\/j.pbb.2023.173523_bb0040","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/13811118.2019.1574688","article-title":"Mental health problems and suicide risk: the impact of acute suicidal affective disturbance","volume":"24","author":"Buckner","year":"2020","journal-title":"Arch. Suicide Res."},{"issue":"1","key":"10.1016\/j.pbb.2023.173523_bb0045","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3934\/Neuroscience.2021005","article-title":"The biological pathways of Alzheimer disease: a review","volume":"8","author":"Calabr\u00f2","year":"2020","journal-title":"AIMS Neurosci."},{"issue":"Suppl. 1","key":"10.1016\/j.pbb.2023.173523_bb0050","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0165-1781(14)70005-8","article-title":"Optimizing the management of depression: primary care experience","volume":"220","author":"Cameron","year":"2014","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.pbb.2023.173523_bb0055","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00441-011-1230-6","article-title":"Dysfunction of TGF-\u03b21 signaling in Alzheimer\u2019s disease: perspectives for neuroprotection","volume":"347","author":"Caraci","year":"2012","journal-title":"Cell Tissue Res."},{"issue":"50","key":"10.1016\/j.pbb.2023.173523_bb0060","doi-asserted-by":"crossref","first-page":"E6983","DOI":"10.1073\/pnas.1517045112","article-title":"PSD-95 family MAGUKs are essential for anchoring AMPA and NMDA receptor complexes at the postsynaptic density","volume":"112","author":"Chen","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.pbb.2023.173523_bb0065","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11481-017-9732-y","article-title":"TGF-\u03b21 Neuroprotection via inhibition of microglial activation in a rat model of Parkinson's disease","volume":"12","author":"Chen","year":"2017","journal-title":"J. Neuroimmune Pharmacol."},{"issue":"7","key":"10.1016\/j.pbb.2023.173523_bb0070","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/carcin\/21.7.1423","article-title":"Roles of JNK, p38 and ERK mitogen-activated protein kinases in the growth inhibition and apoptosis induced by cadmium","volume":"21","author":"Chuang","year":"2000","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.pbb.2023.173523_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-45971-w","article-title":"PSD-95 deficiency disrupts PFC-associated function and behavior during neurodevelopment","volume":"9","author":"Coley","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pbb.2023.173523_bb0080","unstructured":"CTD Gene-Disease Associations, n.d. CTD GENE-DISEASE ASSOCIATIONS (n.d.). Harmonizome. Dispon\u00edvel em: <https:\/\/maayanlab.cloud\/Harmonizome\/gene_set\/Depressive Disorder\/CTD Gene-Disease Associations>. Acesso em: 14 abr. 2022."},{"issue":"2","key":"10.1016\/j.pbb.2023.173523_bb0085","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1021\/acs.jproteome.8b00702","article-title":"Cytoscape StringApp: network analysis and visualization of proteomics data","volume":"18","author":"Doncheva","year":"2019","journal-title":"J. Proteome Res."},{"issue":"2","key":"10.1016\/j.pbb.2023.173523_bb0090","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.neuron.2006.09.012","article-title":"Synapse-specific and developmentally regulated targeting of AMPA receptors by a family of MAGUK scaffolding proteins","volume":"52","author":"Elias","year":"2006","journal-title":"Neuron"},{"issue":"8","key":"10.1016\/j.pbb.2023.173523_bb0095","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1176\/appi.ajp.2016.16050581","article-title":"Further investigation of ketamine","volume":"173","author":"Freedman","year":"2016","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.pbb.2023.173523_bb0100","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.drudis.2016.01.016","article-title":"Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity","volume":"21","author":"Gerhard","year":"2016","journal-title":"Drug Discov. Today"},{"issue":"4","key":"10.1016\/j.pbb.2023.173523_bb0105","doi-asserted-by":"crossref","first-page":"7796","DOI":"10.3390\/ijms16047796","article-title":"Inflammatory biomarkers as differential predictors of antidepressant response","volume":"16","author":"Hashimoto","year":"2015","journal-title":"Int. Journal of Molecular Sciences"},{"key":"10.1016\/j.pbb.2023.173523_bb0110","series-title":"PCN Frontier Review","article-title":"Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective","author":"Hashimoto","year":"2019"},{"key":"10.1016\/j.pbb.2023.173523_bb0115","series-title":"Biochemical Pharmacology","article-title":"Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine","author":"Hashimoto","year":"2020"},{"issue":"11","key":"10.1016\/j.pbb.2023.173523_bb0120","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.biopsych.2007.03.017","article-title":"Increased levels of glutamate in brains from patients with mood disorders","volume":"62","author":"Hashimoto","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2023.173523_bb0125","series-title":"Neuropharmacology","article-title":"A bibliometric analysis of research on (R)-ketamine from 2002 to 2021","author":"He","year":"2022"},{"issue":"2","key":"10.1016\/j.pbb.2023.173523_bb0130","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.tins.2009.11.003","article-title":"mTOR signaling: at the crossroads of plasticity, memory and disease","volume":"33","author":"Hoeffer","year":"2010","journal-title":"Trends Neurosci."},{"issue":"1","key":"10.1016\/j.pbb.2023.173523_bb0135","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bbr.2011.05.035","article-title":"Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression","volume":"224","author":"Koike","year":"2011","journal-title":"Behav. Brain Res."},{"issue":"12","key":"10.1016\/j.pbb.2023.173523_bb0140","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.biopsych.2013.03.026","article-title":"Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond","volume":"73","author":"Krystal","year":"2013","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.pbb.2023.173523_bb0145","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00406-020-01110-5","article-title":"Intravenous arketamine for treatment-resistant depression: open-label pilot study","volume":"271","author":"Leal","year":"2021","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"Suppl. 1","key":"10.1016\/j.pbb.2023.173523_bb0150","first-page":"3","article-title":"The increasing burden of depression","volume":"7","author":"L\u00e9pine","year":"2011","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"1","key":"10.1016\/j.pbb.2023.173523_bb0155","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-020-0769-y","article-title":"Shared genetic etiology underlying Alzheimer's disease and major depressive disorder","volume":"10","author":"Lutz","year":"2020","journal-title":"Translational Psychiatry"},{"issue":"42","key":"10.1016\/j.pbb.2023.173523_bb0160","doi-asserted-by":"crossref","first-page":"11201","DOI":"10.1523\/JNEUROSCI.2255-07.2007","article-title":"Endogenous transforming growth factor \u03b21 suppresses inflammation and promotes survival in adult CNS","volume":"27","author":"Makwana","year":"2007","journal-title":"J.f Neuroscience"},{"issue":"10161","key":"10.1016\/j.pbb.2023.173523_bb0165","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"Malhi","year":"2018","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/j.pbb.2023.173523_bb0170","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11599770-000000000-00000","article-title":"Ketamine for treatment-resistant unipolar depression: current evidence","volume":"26","author":"Mathew","year":"2012","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.pbb.2023.173523_bb0175","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.pnpbp.2006.03.036","article-title":"Correlation between plasma levels of glutamate, alanine and serine with severity of depression","volume":"30","author":"Mitani","year":"2006","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"8","key":"10.1016\/j.pbb.2023.173523_bb0180","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/da.22535","article-title":"Whither ketamine as an antidepressant: panacea or toxin?","volume":"33","author":"Newport","year":"2016","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.pbb.2023.173523_bb0185","series-title":"Inflammation and Regeneration","article-title":"RANKL biology: bone metabolism, the immune system, and beyond","author":"Ono","year":"2020"},{"issue":"W1","key":"10.1016\/j.pbb.2023.173523_bb0190","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/nar\/gkz369","article-title":"G:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update)","volume":"47","author":"Raudvere","year":"2019","journal-title":"Nucleic Acids Research"},{"issue":"2","key":"10.1016\/j.pbb.2023.173523_bb0195","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1128\/MMBR.68.2.320-344.2004","article-title":"ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions","volume":"68","author":"Roux","year":"2004","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"8","key":"10.1016\/j.pbb.2023.173523_bb0200","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.489","article-title":"Bone density and depressive disorder: a meta-analysis","volume":"6","author":"Schweiger","year":"2016","journal-title":"Brain Behav."},{"key":"10.1016\/j.pbb.2023.173523_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.114963","article-title":"Is (R)-ketamine a potential therapeutic agent for treatment-resistant depression with less detrimental side effects? A review of molecular mechanisms underlying ketamine and its enantiomers","volume":"198","author":"Scotton","year":"2022","journal-title":"Biochem. Pharmacology"},{"issue":"11","key":"10.1016\/j.pbb.2023.173523_bb0210","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res."},{"issue":"2","key":"10.1016\/j.pbb.2023.173523_bb0215","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/glia.22435","article-title":"Endogenous transforming growth factor-beta promotes quiescence of primary microglia in vitro","volume":"61","author":"Spittau","year":"2013","journal-title":"GLIA"},{"issue":"1","key":"10.1016\/j.pbb.2023.173523_bb0220","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1172\/JCI88647","article-title":"TGF-\u03b21 modulates microglial phenotype and promotes recovery after intracerebral hemorrhage","volume":"127","author":"Taylor","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.pbb.2023.173523_bb0225","unstructured":"U.S. Food and Drug Administration, n.d. U.S. FOOD AND DRUG ADMINISTRATION. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor\u2019s office or clinic. Dispon\u00edvel em: <https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified>. Acesso em: 4 dez. 2021."},{"issue":"9","key":"10.1016\/j.pbb.2023.173523_bb0230","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1007\/s12035-019-1524-3","article-title":"The ERK pathway: molecular mechanisms and treatment of depression","volume":"56","author":"Wang","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.pbb.2023.173523_bb0235","series-title":"Molecular Psychiatry","article-title":"Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor","author":"Wei","year":"2022"},{"key":"10.1016\/j.pbb.2023.173523_bb0240","unstructured":"World Health Organization, n.d.WORLD HEALTH ORGANIZATION (n.d.). Depression and other common mental disorders: global health estimates. Dispon\u00edvel em: <https:\/\/apps.who.int\/iris\/handle\/10665\/254610>. Acesso em: 7 dez. 2022."},{"issue":"5","key":"10.1016\/j.pbb.2023.173523_bb0245","article-title":"Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model","volume":"368","author":"Xiong","year":"2019","journal-title":"Behav. Brain Research"},{"issue":"9","key":"10.1016\/j.pbb.2023.173523_bb0250","doi-asserted-by":"crossref","first-page":"pp","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Trans. Psychiatry"},{"issue":"1","key":"10.1016\/j.pbb.2023.173523_bb0255","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.biopsych.2017.05.016","article-title":"Mechanistic target of rapamycin\u2013independent antidepressant effects of (R)-ketamine in a social defeat stress model","volume":"83","author":"Yang","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2023.173523_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2020.00082","article-title":"The role of BDNF on neural plasticity in depression","volume":"14","author":"Yang","year":"2020","journal-title":"Front. Cell. Neurosci."},{"issue":"3","key":"10.1016\/j.pbb.2023.173523_bb0265","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/s41380-021-01377-7","article-title":"Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine","volume":"27","author":"Yao","year":"2022","journal-title":"Mol. Psychiatry"},{"issue":"7604","key":"10.1016\/j.pbb.2023.173523_bb0270","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.pbb.2023.173523_bb0275","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pbb.2023.173523_bb0280","series-title":"Neuropharmacology","article-title":"Arketamine, a new rapid-acting antidepressant: a historical review and future directions","author":"Zhang","year":"2022"},{"key":"10.1016\/j.pbb.2023.173523_bb0285","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pbb.2013.11.033","article-title":"R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine","volume":"116","author":"Zhang","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"11","key":"10.1016\/j.pbb.2023.173523_bb0290","first-page":"1025","article-title":"Role of inflammatory bone markers in the antidepressant actions of (R)-ketamine in a chronic social defeat stress model","volume":"21","author":"Zhang","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.pbb.2023.173523_bb0295","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-020-0733-x","article-title":"Essential role of microglial transforming growth factor-\u03b21 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-\u03b21","volume":"10","author":"Zhang","year":"2020","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.pbb.2023.173523_bb0300","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06224-y","article-title":"Silencing of TGF\u03b2 signalling in microglia results in impaired homeostasis","volume":"9","author":"Z\u00f6ller","year":"2018","journal-title":"Nature Communications"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305723000102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305723000102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:44:12Z","timestamp":1758775452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305723000102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":60,"alternative-id":["S0091305723000102"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2023.173523","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differentially regulated targets in the fast-acting antidepressant effect of (R)-ketamine: A systems biology approach","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2023.173523","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173523"}}